|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1993-11-19
|
|
pubmed:abstractText |
Neurofibromatosis evolution is described in relation to the factors that may favour its expansion and immune modifications. NF1 monitorization should employ periodic clinical and immune surveillance. Such an approach would allow the application of immunomodulating treatment (e.g. adapted therapy) only when indicated, thereby reducing its duration and potentiating its efficacy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0031-0808
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
80-5
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8414628-Adolescent,
pubmed-meshheading:8414628-Adult,
pubmed-meshheading:8414628-Aged,
pubmed-meshheading:8414628-Antigen-Antibody Complex,
pubmed-meshheading:8414628-Complement C3,
pubmed-meshheading:8414628-Female,
pubmed-meshheading:8414628-Humans,
pubmed-meshheading:8414628-Immune System,
pubmed-meshheading:8414628-Immunoglobulins,
pubmed-meshheading:8414628-Leukocyte Count,
pubmed-meshheading:8414628-Male,
pubmed-meshheading:8414628-Middle Aged,
pubmed-meshheading:8414628-Neurofibromatosis 1
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Immunological and clinical surveillance in Recklinghausen's neurofibromatosis (NF1).
|
|
pubmed:affiliation |
Department of Orthopaedics, Niguarda Hospital, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article
|
